MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J H GlickM M Oken

Abstract

To compare the efficacy of sequential mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) followed by doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) versus the MOPP/ABV hybrid regimen in advanced-stage Hodgkin's disease. A total of 737 patients with previously untreated stages III2A, IIIB, IVA, or IVB Hodgkin's disease and patients in first relapse after radiotherapy were prospectively randomized to sequential MOPP-ABV or MOPP/ABV hybrid. Of 691 eligible patients, 344 received the sequential regimen and 347 received the hybrid. The overall response rate was 95%, with complete responses (CRs) in 79%: 83% on the MOPP/ABV hybrid and 75% on the sequential MOPP-ABVD arm (P = .02). With a median follow-up time of 7.3 years, the 8-year failure-free survival (FFS) rates were 64% for MOPP/ABV hybrid and 54% far sequential MOPP-ABVD (P = .01; 0.69 relative risk of failure, comparing MOPP/ABV hybrid v MOPP-ABVD). The 8-year overall survival rate was significantly better for the MOPP/ABV hybrid (79%) as compared with sequential MOPP-ABVD (71%) (P = .02; relative risk, 0.65). MOPP/ABV hybrid had significantly more life-threatening or fatal neutropenia and pulmonary toxicity than the sequential MOPP-ABVD arm, which...Continue Reading

Citations

Nov 20, 2002·British Journal of Haematology·Ayad AtraUNKNOWN UKCCSG/Hodgkin's Disease Group
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M SieberUNKNOWN German Hodgkin's Lymphoma Study Group
Dec 12, 2003·European Journal of Haematology·Ingrid GlimeliusGunilla Enblad
Aug 31, 2006·Yonsei Medical Journal·June-Won CheongJee Sook Hahn
Aug 19, 2007·Leukemia & Lymphoma·Lieselot BrepoelsGregor Verhoef
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas EngertMarkus Löffler
Mar 29, 2002·Hematological Oncology·Henry C Fung, Auayporn P Nademanee
Nov 28, 2001·Hematology·J M ConnorsS J Horning
Sep 7, 2000·Journal of Clinical Pharmacology·J P DutcherP H Wiernik
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J HorningP Cassileth
Aug 6, 2008·Nature Clinical Practice. Oncology·Andrew M EvensVolker Diehl
Nov 6, 2010·Expert Opinion on Pharmacotherapy·Bharti Rathore, Marshall E Kadin
Jun 13, 2003·The New England Journal of Medicine·Berthe M P AlemanUNKNOWN European Organization for Research and Treatment of Cancer Lymphoma Group
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paolo G GobbiUNKNOWN Intergruppo Italiano Linfomi
Jul 10, 1999·Current Opinion in Hematology·R G Bociek, J O Armitage
May 8, 2008·Current Treatment Options in Oncology·Michael R Olson, Sarah S Donaldson
Jul 1, 2007·Current Hematologic Malignancy Reports·Bruce D Cheson
Apr 25, 2009·The Cancer Journal·Pamela SeamVincent T Devita
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bruce D Cheson, George P Canellos
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paolo G GobbiMassimo Federico
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Volker Diehl
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David B DugganBruce A Peterson
May 18, 2001·Best Practice & Research. Clinical Haematology·E J Dann, J M Rowe
Feb 13, 2010·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Gerhard SissolakPeter Jacobs

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved